Adaptive Biotechnologies Q1 revenue $38.6M (+0.5% YoY); net loss widens to $62.8M

Adaptive Biotechnologies Corp

2023-Q1 EPS reported -$0.44 revenue$38,620,000

clonoSEQ test volume grew 45% YoY and 12% QoQ; MRD regulatory milestone revenue of $3.0M from partner drug approval.
T-Detect Lyme sensitivity 54% vs SOC 30% at 99% specificity; launch planned for 2022 Lyme season.
Entered T-MAP collaboration with Janssen for RSV vaccine program; appointed Tycho Peterson as CFO.
Revenue guidance for FY2022 reaffirmed at $185-195M; cash and securities $500.7M as of March 31.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.